Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. J of Skin [Internet]. 2020 Oct. 27 [cited 2025 May 22];4(6):s108. Available from: https://skin.dermsquared.com/skin/article/view/1081